KBC Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

KBC Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Hold	3,064	–	–	﹤0.01%	1330
2026 Q1	$111K	Hold	3,064	–	–	﹤0.01%	1260
2025 Q4	$143K	Hold	3,064	–	–	﹤0.01%	1066
2025 Q3	$128K	Hold	3,064	–	–	﹤0.01%	1117
2025 Q2	$88K	Sell	3,064 -1,018	-25%	-$31.4K	﹤0.01%	1279
2025 Q1	$137K	Buy	4,082 +370	+10%	+$13.8K	﹤0.01%	1293
2024 Q4	$190K	Buy	3,712 +1,519	+69%	+$85K	﹤0.01%	1156
2024 Q3	$112K	Buy	2,193 +407	+23%	+$21K	﹤0.01%	1213
2024 Q2	$80K	Hold	1,786	–	–	﹤0.01%	1305
2024 Q1	$84K	Buy	+1,786	New	+$69.9K	﹤0.01%	1219

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's CRNX Position: Q2 2026 in Review

KBC Group held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 3,064 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1330.

KBC Group first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $190K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

KBC Group held 3,064 shares of Crinetics Pharmaceuticals worth $115K as of Q2 2026.
KBC Group left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1330 holding.
KBC Group first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
KBC Group's Crinetics Pharmaceuticals position peaked at $190K in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.